LEADERSHIP TEAM
- JAMES CALLAWAYPh.D., Head of Development
- Former Senior Executive for AD Immunotherapy Program at Elan (AN-1792)
- Former President and CEO of Cebix, Inc. and ArmaGen, Inc.
- Secured U.S. and E.U. drug approvals
- LON S. SCHNEIDERM.D., Medical Director
- Director of the State of CA USC Alzheimer's Disease Center
- Director of the Clinical Core of the NIA Alzheimer's Disease Research Center
- Principal Investigator of the CATIE program
- MICHAEL AGADJANYANPh.D., Sc.D., President
- Head of the Immunology Department at the Institute for Molecular Medicine, CA
- Over 20 years of central nervous system and 47 years of immunology experience
- Launched cancer treatment, vaccine, and other biotech companies
- ROMAN KNIAZEVKauffman Fellow, CEO
- Former Investment Director of a $5B European VC fund
- Launched multiple healthcare companies
- DAVID H. CRIBBSPh.D., Scientific Director
- Professor in Residence at the Neurology School of Medicine and Member of the MiND Institute at the University of California, Irvine
- Focused on age-related Alzheimer’s disease research
- ANAHIT GHOCHIKYANPh.D., Chief Scientific Officer
- Assistant Professor in the Immunology Department at the Institute for Molecular Medicine, CA
- Former Postdoctoral Fellow at the University of Nantes, France
- Over 18 years of central nervous system experience
- Focused on antibody-mediated Aβ, tau, and α-synuclein clearance research
- GURIQ BASIPh.D., Director of Regulatory Compliance
- Former CSO of Elan Pharmaceuticals
- Former SVP of Adverum BioTechnology
- ALEXEY DANGPh.D., Advisor
- Former CEO of Cancer Compass, part of Cancer Treatment Centers of America
- Former McKinsey Partner and Amazon/AWS executive
- Launched 15+ corporate ventures